Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 7/20 | 0.34 |
| ▸ | NPY1R | P25929 | 5/20 | 0.34 |
| ▸ | NPY2R | P49146 | 4/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416266 | 0.88 | DPP7 (0.47) | DPP7MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL13416749 | 0.87 | DPP7 (0.46) | DPP7MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL13416888 | 0.86 | NPY4R (0.33) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL14135433 | 0.83 | GNAI3 (0.51) | DPP7MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL22903238 | 0.82 | DPP7 (0.46) | DPP7MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL13396385 | 0.81 | NOS1 (0.41) | DPP7MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL23626315 | 0.79 | DPP7 (0.61) | DPP7MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL23610947 | 0.79 | DPP7 (0.61) | DPP7MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL10727004 | 0.79 | DPP7 (0.50) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL13416254 | 0.78 | MEN1 (0.45) | DPP7MEN1KMT2ACA2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | DPP7 3437/4885MEN1 615/4885KMT2A 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.